Halozyme Therapeutics Inc. (HALO)

18.86
NASDAQ : Health Technology
Prev Close 19.16
Day Low/High 18.64 / 19.12
52 Wk Low/High 11.41 / 21.48
Avg Volume 945.50K
Exchange NASDAQ
Shares Outstanding 143.73M
Market Cap 2.75B
EPS 0.50
P/E Ratio 42.58
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,401,809 share decrease in total short interest for Halozyme Therapeutics Inc , to 10,232,867, a decrease of 12.05% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Halozyme Therapeutics Reaches Analyst Target Price

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $20.11, changing hands for $20.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018

Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018

CONTINUES TO EXPECT TARGET NUMBER OF PFS EVENTS IN HALO-301 REGISTRATION TRIAL TO BE REACHED IN LATE Q4

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Roku, Sierra Wireless, Visa, Cimarex Energy, First Solar, Halozyme Therapeutics.

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Don't buy big here and don't buy all at once, but it's not too late to ride this bull to profits, says Jim Cramer.

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc.

Exxon, Chevron, Cimarex Energy: 'Mad Money' Lightning Round

Exxon, Chevron, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Exxon, Chevron, Cimarex Energy, Skechers USA, and Halozyme Therapeutics.

Trump Doesn't Get All the Credit: Cramer's 'Mad Money' Recap (Wed 11/8/17)

Trump Doesn't Get All the Credit: Cramer's 'Mad Money' Recap (Wed 11/8/17)

Jim Cramer says President Trump has been a great salesman, but when we look at winning stocks, it's the strong CEOs who are driving success.

Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology

Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology

-- Subcutaneous injection has potential to reduce multi-hour infusion to 5-minutes--

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

In this sometimes fickle market, supply and demand are still at play.

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Proposals are having an effect ahead of afternoon announcement.

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.

Good Stocks Are There for the Picking

Good Stocks Are There for the Picking

Focus on what could go right.

There Are Good Opportunities in Stock Picking

There Are Good Opportunities in Stock Picking

The indices may need a rest, but stock-pickers have an edge.

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.

TheStreet Quant Rating: B- (Buy)